The Global Initiative of Asthma (GINA) recommends that short-acting beta 2-agonist (SABA)
monotherapy should no longer be prescribed, and that as-needed combination inhaled …

The long-term goal of asthma management is to achieve disease control, comprised of the
assessment of two main domains: 1) symptom control and 2) future risk of adverse …

Short-acting β2 agonists (SABAs) have been a mainstay of asthma treatment since the
1950s, and have been mainly recommended as-needed for symptom relief alongside daily …

Abstract Background The 2021 Global Initiative for Asthma (GINA) report recommends 2
treatment tracks depending on choice of reliever therapy: either inhaled corticosteroid …

Background The Global Initiative for Asthma and National Asthma Education and Prevention
Program recently made paradigm-shifting recommendations regarding inhaler management …

Introduction Pharmacological asthma management focuses on the use of inhaled
corticosteroid (ICS)-containing therapies, which reduce airway inflammation and provide …

Purpose of Review A modified Delphi process was undertaken to provide a US expert-led
consensus to guide clinical action on short-acting beta2-agonist (SABA) use. This comprised …

Known for their pre-occupation with body image, self-identity creation, peer acceptance, and
risk-taking behaviors, adolescents with asthma face unique challenges. Asthma is a …

Inhaled therapy is the cornerstone of the management of asthma and chronic obstructive
pulmonary disease (COPD). Drugs such as bronchodilators and corticosteroids are …

Introduction Current treatment for moderate–severe asthma with inhaled corticosteroid (ICS)-
based therapy can follow two strategies: a single inhaler maintenance and reliever therapy …